K. Sarouei

发表

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

R. McCord, U. Abadi, G. Sellam, 2020 .

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

I. Flinn, N. Bartlett, C. Cheah, 2020 .

MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES

R. McCord, K. Giannopoulos, U. Abadi, 2021, Hematological Oncology.